Eribulin + TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer (NSCLC)
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Trial Timeline
Dec 9, 2011 → May 2, 2016
NCT ID
NCT01454934About Eribulin + TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Eribulin + TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed is a phase 3 stage product being developed by Eisai for Non-Small Cell Lung Cancer (NSCLC). The current trial status is completed. This product is registered under clinical trial identifier NCT01454934. Target conditions include Non-Small Cell Lung Cancer (NSCLC).
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer (NSCLC) were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01454934 | Phase 3 | Completed |
Competing Products
20 competing products in Non-Small Cell Lung Cancer (NSCLC)